FY2028 EPS Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Boosted by HC Wainwright

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – HC Wainwright increased their FY2028 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Wednesday, May 8th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.37 per share for the year, up from their previous forecast of $0.33. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.51) per share.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $1.08. 2,286,000 shares of the stock were exchanged, compared to its average volume of 2,661,800. The stock’s fifty day moving average is $1.17 and its 200 day moving average is $0.94. The stock has a market cap of $180.53 million, a PE ratio of -1.52 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.34 and a current ratio of 5.34. X4 Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $2.58.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.05.

Institutional Trading of X4 Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Bain Capital Life Sciences Investors LLC lifted its position in shares of X4 Pharmaceuticals by 6.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock worth $14,184,000 after purchasing an additional 955,196 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of X4 Pharmaceuticals by 14.5% in the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after purchasing an additional 668,422 shares in the last quarter. Kingdon Capital Management L.L.C. lifted its position in shares of X4 Pharmaceuticals by 76.0% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after purchasing an additional 1,500,000 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of X4 Pharmaceuticals in the third quarter worth approximately $678,000. Finally, Barclays PLC lifted its position in shares of X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock worth $417,000 after purchasing an additional 294,255 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 49,678 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the transaction, the chief executive officer now owns 765,068 shares in the company, valued at approximately $673,259.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at approximately $53,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the sale, the chief executive officer now directly owns 765,068 shares of the company’s stock, valued at $673,259.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 185,708 shares of company stock worth $170,428. Insiders own 1.08% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.